Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
B-G. Kim
Observed names:
B-G Kim,
B.-G. KIM,
B.-G. Kim,
B.G. Kim,
BG Kim
Institutions:
Samsung Medical Center,
Kangbuk Samsung Hospital,
Sungkyunkwan University
Observed institutions:
Inha University,
Samsung Medical Center,
SNUH SMG-SNU Boramae Medical Center,
Kangbuk Samsung Hospital,
Inha University Hospital,
Chung-Ang University,
Sungkyunkwan University
show all 7
OpenAlex ID:
A5108985682
Increased expression of pAKT is associated with radiation resistance in cervical cancer
2006
·
T-J Kim
, J-W Lee
, et al.
·
British Journal of Cancer
·
135
PDF
811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1
2020
·
S. Banerjee
, K.N. Moore
, et al.
·
Annals of Oncology
·
74
PDF
Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival
2012
·
C H Choi
, J-J Choi
, et al.
·
British Journal of Cancer
·
55
PDF
Profiling of differentially expressed genes in human uterine leiomyomas
2005
·
E.-J. Lee
, G. Kong
, et al.
·
International Journal of Gynecological Cancer
·
44
Intravenous Lidocaine for Effective Pain Relief after Inguinal Herniorrhaphy: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study
2011
·
H Kang
, B-G Kim
·
Journal of International Medical Research
·
37
Intraperitoneal Ropivacaine for Effective Pain Relief after Laparoscopic Appendectomy: A Prospective, Randomized, Double-blind, Placebo-controlled Study
2010
·
H Kang
, B-G Kim
·
Journal of International Medical Research
·
32
PDF
A pilot study of three-cycle consolidation chemotherapy with paclitaxel and platinum in epithelial ovarian cancer patients with clinical complete response after paclitaxel and platinum chemotherapy
2006
·
S.-J. LEE
, J.-W. LEE
, et al.
·
International Journal of Gynecological Cancer
·
16
517O Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial
2022
·
P. DiSilvestro
, S. Banerjee
, et al.
·
Annals of Oncology
·
9
788P Pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3)
2024
·
N. Ngoi
, J-Y. Lee
, et al.
·
Annals of Oncology
·
8
PDF
LBA32 Efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer (phase II): Safe and effective in both PD-L1 positive and negative
2022
·
S. Lee
, M-C. Lim
, et al.
·
Annals of Oncology
·
7
PDF
Pad – a new self-collection device for human papillomavirus
2007
·
S R Kim
, S Y Song
, et al.
·
International Journal of STD & AIDS
·
7
A Comparison of Laparoscopic-Assisted Radical Vaginal Hysterectomy and Laparoscopic Radical Hysterectomy in the Treatment of Cervical Cancer
2011
·
C.H. Choi
, J-W Lee
, et al.
·
Journal of Minimally Invasive Gynecology
·
6
PDF
23O A randomized, phase III, double-blind study of chemoradiotherapy with or without pembrolizumab in patients with high-risk, locally advanced, cervical cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047): Results for patients enrolled in Asia
2024
·
Y. Xiang
, K. Hasegawa
, et al.
·
ESMO Open
·
5
PDF
40MO First-line (1L) durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib for endometrial cancer (EC) (DUO-E): Objective response rate (ORR), duration of response (DoR) and time to treatment discontinuation or death (TDT) by mismatch repair (MMR) status
2024
·
E. Van Nieuwenhuysen
, H.S. Chon
, et al.
·
ESMO Open
·
4
732P Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E
2024
·
S.V. Blank
, M. McCollum
, et al.
·
Annals of Oncology
·
3
PDF
234O Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1
2020
·
M.L. Friedlander
, K. Moore
, et al.
·
Annals of Oncology
·
3
Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial
2019
·
K. Moore
, N. Colombo
, et al.
·
International Journal of Gynecological Cancer
·
3
Effects of Preserving the Posterior Branch of the Greater Auricular Nerve at Parotidectomy on Postoperative Peri-Auricular Sensation
2005
·
Jian‐Ming Yang
, Chang Jh
, et al.
·
Korean Journal of Otorhinolaryngology - Head and Neck Surgery
·
3
738P Global, phase Ib dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced (a) endometrial cancer (EC) that progressed on platinum-based chemotherapy (CTx) and an anti-PD-(L)1 immunotherapy (IO)
2024
·
J-Y. Lee
, K. Hasegawa
, et al.
·
Annals of Oncology
·
2
PDF
LBA8 Preliminary efficacy of pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3)
2023
·
N.Y. Ngoi
, J-Y. Lee
, et al.
·
Annals of Oncology
·
2
101P Real-world prevalence of MSI-H/dMMR across 6 different tumor types in Asia
2022
·
D.S. Tan
, Y.M. Kim
, et al.
·
Annals of Oncology
·
2
Current Status and the Future of the Irradiation Services in the HANARO Reactor
2004
·
Y. H. Kang
, B-G. Kim
, et al.
·
University of North Texas Digital Library (University of North Texas)
·
2
1092P Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in patients with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: Durable long-term survival from the OPEB-01/APGOT-OV4 trial
2025
·
Y-N. Kim
, S.I. Kim
, et al.
·
Annals of Oncology
·
1
PDF
261MO Real-world data on prevalence of MSI-H/dMMR across 6 solid tumor types in Asia
2022
·
D.S.S.P. Tan
, Y.M. Kim
, et al.
·
Annals of Oncology
·
1
Response After Repeated Ketamine Injections in a Rat Model of Neuropathic Pain
2022
·
NE Kim
, BG Kim
, et al.
·
Physiological Research
·
1
PDF
Show more works
View as search
Works count:
59
Citation count:
469
H-index:
8
I10-index:
7
Year
Topic
Type